comparemela.com

Latest Breaking News On - Nathalie franchimont - Page 1 : comparemela.com

Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting

BOSTON (BUSINESS WIRE) May 23, 2024

United statesCindy fungMarcus noelNathalie franchimontNimbus therapeuticsAmerican society of clinical oncologyAmerican societyClinical oncologyAnnual meetingChief medical officerDevelopmental therapeuticsMolecularly targeted agentsBusiness wire

Nimbus Therapeutics Appoints Nathalie Franchimont, M D , Ph D , as Chief Medical Officer

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace

United kingdomNathalie franchimontJeb keiperUniversity of liUniversity of connecticut school medicineEarly development unitImmunology development unitYale university school of medicineIndications researchSclerosis researchClinical developmentNimbus therapeuticsChief medicalChief executive officerSenior vice presidentMultiple sclerosis

The New England Journal of Medicine Publishes Second

Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with.

United statesUnited kingdomCharles weissmannWalter gilbertHeinz schallerNathalie franchimontRichard furieAshleigh kossBarry rubensteinMike henckeKenneth murrayCenters for diseasePrevention national lupus registriesBiogen incImmunology development unit at biogenExchange commission

Mixed Results for Novel Lupus Drug in Mid-Stage Trial

Developer of litifilimab, an anti-BDCA2 antibody, presses ahead despite phase II hiccups

New yorkUnited statesUnited kingdomLos angelesDanielj wallaceNathalie franchimontJohn geverRichard furieNorthwell health in great neckSinai medical centerNorthwell healthGreat neckNew england journalCedars sinai medical centerCutaneous lupus erythematosus disease areaSeverity index

Anti-BDCA2 Antibody Meets Primary Endpoint in Phase 2 CLE Trial

In the phase 2 study, improvements in the CLASI-A scores were seen in patients randomly assigned to subcutaneous litifilimab.

United statesAlisa femiaNathalie franchimontGilead sciencesUniversity of pennsylvaniaUniversity of leedsYork university grossman school of medicineCutaneous lupus erythematosus disease areaSeverity indexNew england journalNew york university grossman schoolEdward vitalSystemic lupus erythematosusClinical researchClinical trialsLinical studies

vimarsana © 2020. All Rights Reserved.